Bio-Matrix Scientific Group Sees Share Volume Triple Its Three Month Average

Follow this company

Companies Mentioned

06/12/2014 [ACCESSWIRE]

Bio-Matrix Scientific Group, Inc. (OTCPINK: BMSN) saw its share volume skyrocket on June 11th with 83,404,568 shares exchanging hands, more than triple its three month daily average volume of 25,355,526 shares.


Yesterday, Regen BioPharma, Inc., a majority owned subsidiary of Bio-Matrix Scientific Group, Inc., announced data demonstrating greater than 75% survival rate in HLA mismatched hearts by combining silencing of two genes on dendritic cells, CD40 and CD80. The experimental animal studies demonstrated the possibility of using gene silencing as a means of avoiding the need for lifelong immune suppression, one of the major causes of adverse reactions associated with heat transplantation.


"Although Regen's focus with Dr. Min is the development of technology licensed from Benitec BioPharma to stimulate the immune system, in the form of dCellVax, the current publication illustrates the broad applicability of gene silencing technology, not only for immune stimulation, but also for targeted immune suppression," said Dr. Thomas Ichim, Chief Scientific Officer of Regen BioPharma. "In the case of dCellVax we are blocking immune suppressive genes to induce immune stimulation, whereas in this case, we silenced immune stimulatory genes to block only the part of the immune system that is responsible for rejection of heart transplants."


BMSN closed the day at $.0041 on June 11th, 10.81% higher than its previous close of $.0037. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:


Actionview International Acquires MD Construction Company


Actionview International, Inc. (OTCPINK: AVEW), now known as AVEW Holdings, Inc., saw it share volume continue its upward trend with 129,089,568 shares exchanging hands, four times higher than its three month daily average volume of 32,708,758 shares.


Just yesterday, AVEW Holdings announced that the company has acquired MD Construction Company, a Texas-based company that operates as an outdoor living contractor and indoor remodel business headquartered in Austin, Texas. MD Construction is a two-year-old business with an excellent reputation in the outdoor living and remodel industry. MD Construction has enjoyed a 150% overall growth in revenues over the past year. MD Construction will operate as AUSTIN PATIO & OUTDOOR LIVING -- a subsidiary of AVEW Holdings Inc.


Commenting on the transaction, President, James T. Ling, explained, "We are excited about this transaction because it compliments our current business model and will contribute to AVEW's outdoor construction platform and to bottom line profits. Austin Patio and Outdoor Living will contribute to AVEW with its construction business and also bring in additional revenues from its operations."


AVEW closed the day at $.0022 on June 11th. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:


Amarantus Bioscience Holdings Announces Addition of Cavendish Global As Partner For Coalition For Concussion Treatment


Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) saw its share volume remain strong on June 11th with 6,869,999 shares exchanging hands, slightly higher than its three month daily average volume of 4,947,193 shares.


Yesterday Amarantus and Brewer Sports International announced the addition of Cavendish Global as partner at the 3rd #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, on Thursday, July 31, 2014 at the United Nations in New York City, NY. The summit will be focused on the emerging hypothesis that brain injury may increase the risk of Alzheimer's disease.


Mr. Michael Moffat, Cavendish co-founder and President explains, "Brain disorders affect more than 60 million Americans, that's more than one in four Americans suffering from mental illness or brain injury. From autism and Alzheimer's disease to traumatic brain injury (TBI) and post-traumatic stress (PTS), brain ailments cost the U.S. close to $1 trillion each year. Leading scientists have uncovered compelling evidence of the link between Traumatic Brain Injuries and Alzheimer's and Parkinson's disease." Moffat emphasizes, "Cancer and heart disease affect fewer people, yet receive three times more funding support than brain diseases. With recent advances in understanding the link between TBI and brain ailments, there has never been a better time for pro-social family offices and foundations to make a real difference by accelerating the development of new diagnostics and treatments through increased grant-giving and philanthropy in this important area. Cavendish is committed to help make this happen."


AMBS closed the day at $.1023 on June 11th, 3.86% higher than its previous close of $.0985. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:




ABOUT US: issues momentum alerts on stocks that can provide gains to day traders. provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.


Timing is everything when trading Penny Stocks. Gain an Edge by joining the newsletter and receiving alerts from a Pro-Active team of researchers. believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.


Simply sign up for free and start receiving exclusive alerts.


Subscribe Here:



Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.


Leave a comment...

Your Name